Company profile
ARROWHEAD PHARMACEUTICALS, INC.
NASDAQ:ARWRBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| REDEMPLO | approved | $75.3MQ2 2026 | 0 | — |
| BERSACAPAVIR | phase1_2 | — | 13 | completed, terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (49)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07662096 | phase1 | recruiting | 2026-06-25 | 2028-07-01 | Arrowhead Pharmaceuticals | A First-In-Human Study of ARO-033 in Adult Participants |
| NCT06937203 | phase1_2 | recruiting | 2025-05-09 | 2027-02-01 | Arrowhead Pharmaceuticals | A First-In-Human Study of ARO-ALK7 in Adults With Obesity With and Without Type 2 Diabetes Mellitus |
| NCT06700538 | phase1_2 | recruiting | 2024-12-04 | 2027-09-17 | Arrowhead Pharmaceuticals | A First-In-Human Study of ARO-INHBE in Adults With Obesity With and Without Type 2 Diabetes Mellitus |
| NCT02604199 | phase2 | terminated | 2015-09-01 | 2017-01-01 | Arrowhead Pharmaceuticals | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection |
| NCT02604212 | phase2 | terminated | 2015-11-01 | 2016-12-01 | Arrowhead Pharmaceuticals | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 219947 | 2025-11-18 | NDA | ARROWHEAD PHARMACEUTICALS INC | |||||
Loading… | ||||||||